Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection
Open Access
- 1 May 1999
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 13 (5) , 661-665
- https://doi.org/10.1046/j.1365-2036.1999.00509.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Who Should Be Treated for Helicobacter pylori Infection? A Review of Consensus Conferences and GuidelinesGastroenterology, 1997
- Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcerGut, 1997
- The role of antisecretory drugs in the treatment of Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 1997
- Efficacy and tolerability of a one‐week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcerAlimentary Pharmacology & Therapeutics, 1997
- safety of bismuth in the treatment of gastrointestinal diseasesAlimentary Pharmacology & Therapeutics, 1996
- Endoscopic papillectomy: a novel approach to difficult cannulation.Gut, 1996
- Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group [see comments]Alimentary Pharmacology & Therapeutics, 1996
- GR122311X (ranitidine bismuth citrate), a new drug for the treatment of duodenal ulcerAlimentary Pharmacology & Therapeutics, 1995
- Effect of Triple Therapy (Antibiotics plus Bismuth) on Duodenal Ulcer HealingAnnals of Internal Medicine, 1991